Ocular Therapeutix
OCUL
68 hedge funds and large institutions have $88.6M invested in Ocular Therapeutix in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 9 closing their positions.
291% more call options, than puts
Call options by funds: $751K | Put options by funds: $192K
37% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 19
2% more capital invested
Capital invested by funds: $86.5M → $88.6M (+$2.13M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.52% less ownership
Funds ownership: 52.63% → 52.11% (-0.52%)
1% less funds holding
Funds holding: 69 → 68 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$7.64M |
| 2 |
Man Group
London,
United Kingdom
|
+$2.15M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$1.94M |
| 4 |
DAM
Deltec Asset Management
New York
|
+$402K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$281K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$5.55M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.04M |
| 3 |
Millennium Management
New York
|
-$837K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$777K |
| 5 |
Morgan Stanley
New York
|
-$377K |
OCUL Hedge Fund Activity: Q1 2019 in Review
68 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q1 2019, worth a combined $88.6M — up 2.5% from $86.5M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of OCUL and 8 opened new positions — a net loss of 1 holder — while 19 trimmed existing stakes and 26 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $7.64M. The largest seller was Jennison Associates, cutting an estimated $5.55M.
- 68 institutional investors held Ocular Therapeutix (OCUL) as of Q1 2019, down from 69 in Q4 2018.
- Funds reported $88.6M of Ocular Therapeutix stock for Q1 2019, up 2.5% quarter-over-quarter.
- 8 funds opened new Ocular Therapeutix positions in Q1 2019 and 9 closed out, a net change of -1 holder.
- The largest Ocular Therapeutix buyer in Q1 2019 was Opaleye Management, an estimated $7.64M added.
- The largest Ocular Therapeutix seller in Q1 2019 was Jennison Associates, an estimated $5.55M sold.
Based on aggregated 13F filings for Q1 2019.